Member Info for wyndrum

Thats true Neut,
but A: I don't put too much weight on categorical statements by directors. They are pretty nimble and if they see an opportunity they will try and take it. (I ma not saying that is true in this case, I am just saying that what AVCT say and do don't have to be closely aligned if they see an advantage to be gained if a situation has changed)

and B: its not all that ABDX do.
"Abingdon Health plc is a developer and manufacturer of rapid tests across all industry sectors, including healthcare and COVID-19. The principal activity of the Company includes developing, manufacturing and distributing diagnostic devices and providing consultancy services to businesses in the diagnostics sector.)

Anyway, I don't see it as the worse fit. Could be cost savings as well, but who knows. I for one, would not be surprised.

sure, but... its AVCT's aim to do a lot more in this field. As for loss making, again, maybe not. "Materially" better 2nd half coming up.

Borrow £15m at 10% interest. should be self financing?

I guess the point is, if AVCT do want to expand this area of the business then they are going to have to acquire other companies.

This looks potentially cheap,(sorry good value)

I agree with you both about the downside, but AVCT did highlight this in the recent update, so I think its on their radar to continue to build and I got the impression (possibly incorrecttly), that it would be sooner rather than later.

If that is right (i know, if , if , if,), then I think it would have to be self financing and it could be a loan rather than a share raise and therefore not to much of a distraction from TX.

I also think the TX thing is pretty much done in as much as its about administration right now through this and the next part of the trial, rather than development, so it might not be taking up so much of AVCT's resources as we assume?

Going forward if TX does get bought out as a separate entity then it allows AVCT to fall back on the more developed DX business.

Lots of speculation obviously, but I can see a potential route through on this one. (It would also account for a depressed SP if the market thinks there is something going on. Although that is a reach, I know.)

ABDX: "We remain optimistic on the prospects for the lateral flow market. Recent market estimates suggest the lateral flow market will reach nearly $23 billion by 2027 (Source: MarketsandMarkets) and we believe that this will be driven by new product development which will offer further opportunities for the Group to grow its CDMO business for the foreseeable future."

That is a pretty big market. £23b. ABDX valued at £10m. buyout at around £15m? might be a very good fit if AVCT are serious about the DX arm of the business. Looks a good vertical fit as it puts a "one-stop" solution in place, by making, producing and selling tests

They have a history of working together, so AVCT know them and if the results are to be believed then ABDX looks to be turning a corner.

It would be very positive if Harl finishes at 17.5p at least. Its had a couple of goes, so fingers crossed

What? so no dates he gives out are to be given any credence? They might happen, they might not.

It might be this summer it might be next spring?

So given your back tracking where does it make my guess so wrong and "agenda" ridden?

My god you really are pathetic

of course its my opinion.

When has AVCT ever met a deadline?

He indicates its possible DE7 will be needed. So he has given himself the wriggle room.

What if there are delays beyond his control? (Such as patients being too ill to continue).

I am basing my opinion on what has happened before and indeed this trial. Its not cherry picking at all.

6.40 into the interview... (but you already knew that didn't you?)

given historically it always drags on I would go with 3 DE's finishing sometime Q4 with early Q1 start to P1b.

I will be plesantly surprised if its sooner.

cj, I thought that was what AS said in the P Hill interview?

He was talking about that there could be 3 DE's but thought it more likely just 2 and then 2 months to review the data before starting 1pb so as to inform the correct doseage.

"I'm thinking end of P1a should be published. "

I don't think that is likely as AS has said he expects it to take 2 months to collate and examine the data. Publishing it "raw" could make others draw incorrect conclusions. (Otherwise why expect to spend 2 months looking at it?)

looks like they are short of stock (to me, anyway)

RD, I am confused as to when p1b will start. There seem to have been several posts that indicate it could start while p1a is still going but I thought I heard AS say that p1b would not start until the end of DE6 (maybe 7 but unlikely), and then not until about 2 months of data collection.

The SP is stuck I think, because there is no clear sign yet as to believable time lines for the trial to finish, and still no solid confirmation as to how it is to be commercialised.

It could well be AS is relaxed about these potential "road blocks" to the SP as it will be resolved in the stunning results as they are released in the coming months.

In the meantime we wait and hope.

I imagine there will have to be a statement tomorrow as its share moving info.

apparently it caught fire, in which case unlikely to be to do with Harl

Thats alright ripley, we can park it next to the "Nasdaq listing" announcement

It could fall a bit more CI, (21p-23p) but I thought around this price it was worth the punt

(Sometimes the actual precise figure is not hit so its always a judgement as to when to get in. )

Just Hit 23.5p so bought the other tranch

just had a re-look today at ABDX. After a small retrace it broke through 7p and has held at 8p for a little while.

RSI is quite high so maybe a fall back to 7p but if it did I would think that would attract buyers. 9.75p looks like a target to me, so good risk reward anywhere below current 8p I think?

apology accepted

Pedro, I simply responded to a question directly aimed at me.

I am not to know if the poster wants an answer or not, so I take it at face value.

I bought at 111.

Its around a support price now. hopefully it holds.

back to waiting the 138-142p resistance to be cleared Should have sold then, but like the rest here you just keep thinking... surely this time....

Don't spend so much time on this one in a trading sense (in terms of amounts) as I have put that money to work elsewhere. Still holding the 40k core stock and presently about a smallish £7k on the 111 trade.

Plenty of other fish in the sea.